SCHEMBL7202596

SCHEMBL7202596

Cc1ccccc1Oc1ccc(S(=O)(=O)C2CCN(C(N)=O)CC2(O)C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 7/20 0.54
MMP13 P45452 7/20 0.54
TSHR P16473 4/20 0.44
HTT P42858 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GPR55 Q9Y2T6 1/20 0.44
FFAR1 O14842 2/20 0.41
PPARG P37231 1/20 0.41
ADAMTS4 O75173 1/20 0.39
MMP2 P08253 2/20 0.38
MMP3 P08254 2/20 0.38
MMP9 P14780 2/20 0.38
MMP14 P50281 2/20 0.38
MMP12 P39900 1/20 0.38
S1PR2 O95136 1/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
EZH2 Q15910 1/20 0.35
LPAR1 Q92633 1/20 0.35
LPAR5 Q9H1C0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7206530 0.91 TSHR (0.45) MMP1MMP13TSHRHTTSMN1; SMN2
SCHEMBL7207163 0.89 MMP1 (0.45) MMP1MMP13TSHRHTTSMN1; SMN2
SCHEMBL7199674 0.89 MMP1 (0.42) MMP1MMP13HTTSMN1; SMN2FFAR1
SCHEMBL7199700 0.89 MMP1 (0.42) MMP1MMP13SMN1; SMN2ADAMTS4ALDH1A1
SCHEMBL7204562 0.87 MMP13 (0.51) MMP1MMP13HTTSMN1; SMN2FFAR1
SCHEMBL7199692 0.85 PARP10 (0.41) MMP1MMP13MMP2MMP3MMP9
SCHEMBL7203058 0.85 MMP9 (0.47) MMP1MMP13TSHRSMN1; SMN2MMP2
SCHEMBL7202626 0.84 MMP1 (0.57) MMP1MMP13FFAR1ADAMTS4
SCHEMBL7205634 0.84 MMP13 (0.55) MMP1MMP13HTTSMN1; SMN2FFAR1
SCHEMBL7204213 0.83 MMP13 (0.52) MMP1MMP13ADAMTS4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885TSHR 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.